Why is Hims Down? The Regulatory Crackdown Driving HIMS Stock Lower

Extreme Oversold Territory: Unpacking the Hims XTRM Score

When an asset triggers a Weekly XTRM Score of -210.23, it commands immediate attention from technical analysts. The XTRM score is a proprietary indicator designed to measure the severity of a selloff, and any reading below the -200 threshold denotes severe, structural capitulation rather than a routine pullback. For Hims & Hers Health, Inc. (HIMS), this extreme reading highlights a grueling multi-month contraction that has erased billions in market capitalization.

As of early March 2026, Hims is trading at $24.85, representing a steep 65.9% decline from its all-time high of $72.98 reached roughly a year ago on February 18, 2025. While the stock has seen a few sharp counter-trend rallies, the overarching momentum has been heavily skewed to the downside. To understand why Hims is dropping with such intensity, we have to look past the technical damage and unpack the severe regulatory and legal headwinds confronting its core growth engine.

Why is Hims Dropping? The Fundamental Drivers

If you are wondering why Hims is going down despite previously stellar subscriber growth, the answer lies almost entirely in the company's highly lucrative weight-loss segment. Throughout 2024 and early 2025, Hims saw explosive revenue expansion by selling compounded versions of GLP-1 weight-loss drugs like semaglutide. However, a rapid shift in the regulatory landscape in early 2026 dismantled that strategy. The selloff was driven by three compounding factors:

• FDA Crackdown on Compounded GLP-1s: In February 2026, the FDA took aggressive action against the mass-marketing of non-FDA approved compounded GLP-1 drugs. The immediate trigger for Hims occurred when the company unveiled a $49 compounded oral semaglutide pill to rival Wegovy. Just days later, the FDA issued warnings regarding illegal copycat drugs, forcing Hims to abruptly withdraw the product. The FDA followed up in March by sending dozens of warning letters to telehealth companies, effectively closing the regulatory loophole Hims had relied upon.
• Novo Nordisk Lawsuit and Forced Pivot: Compounding the FDA pressure, pharmaceutical giant Novo Nordisk filed a patent infringement lawsuit against Hims in February 2026. While the two companies recently reached a settlement in March 2026—resulting in Hims agreeing to sell the official, FDA-approved Wegovy and Ozempic rather than its own compounded versions—the market realized this pivot fundamentally alters the company's margin profile. Reselling branded drugs strips away the massive profit margins Hims enjoyed when producing its own compounded alternatives.
• Guidance Downgrades: The financial reality of this regulatory wall hit hard during the company's Q4 2025 earnings report. Management issued soft Q1 2026 revenue guidance, citing a $65 million headwind directly related to regulatory changes in how personalized weight-loss products are shipped. The realization that hyper-growth had suddenly slammed into a regulatory ceiling sparked a massive institutional exit.

Hims by the Numbers

To contextualize the current valuation, it is helpful to look at the raw data defining the technical and fundamental landscape for HIMS.

At a 49.0x P/E ratio, Hims is no longer priced for perfection, but it still carries a growth premium. Historically, the stock traded at much higher triple-digit multiples during the peak of its compounded GLP-1 euphoria. Compared to other telehealth peers, a 49x multiple suggests the market still believes in the company's core subscription model and recent international expansion efforts, like its $1.15 billion acquisition of Australian digital health firm Eucalyptus. However, it leaves little room for error if the new branded GLP-1 partnership fails to drive comparable subscriber retention.

Technical Indicators: Navigating the Next Support Level

The technical posture of HIMS presents a complex picture of near-term stabilization masking long-term damage. The Daily RSI currently sits at 65.7, which is approaching overbought territory on the daily timeframe. This recent upward momentum is largely a relief bounce directly tied to the news of the Novo Nordisk settlement, which removed the existential threat of litigation. However, the Weekly RSI of 41.6 and the severely depressed Weekly XTRM Score of -210.23 confirm that the broader macroeconomic trend remains firmly entrenched in a downtrend.

Looking at price action, the critical level to watch is the key support zone at $18.00. The stock recently established pivot lows at $13.74 in late February before the settlement news catalyzed a sharp short-covering rally.

What a Healthy Test of Support Looks Like

If the current relief rally fades, a healthy retest of the $18.00 support level would be characterized by decreasing bearish volume. Currently, daily volume sits at roughly 25.2 million shares, which is 33% below the 30-day average. A slow, low-volume drift down to the $18.00 to $20.00 range, followed by sideways consolidation, would indicate that sellers are exhausted and the market is comfortably digesting the company's new, lower-margin business model.

Risks of a Breakdown

Conversely, if HIMS breaks decisively below the $18.00 level on expanding volume, it would signal that institutional investors are entirely abandoning the stock's growth narrative. A failure to hold $18.00 would open the door for a deeper reversion toward the single digits, potentially testing the all-time low of $2.72 established back in May 2022. This scenario could unfold if upcoming earnings reveal that subscriber churn is accelerating without the draw of cheap, compounded weight-loss drugs.

Outlook: Is Hims Worth Monitoring?

When an asset sheds over 65% of its value, it inevitably starts to draw attention from value-oriented market participants looking for a turnaround. Hims has taken decisive steps to clear the regulatory overhang by abandoning its controversial compounded GLP-1 strategy and partnering directly with Novo Nordisk. This strategic pivot, combined with international acquisitions, provides a tangible path forward for the business.

However, an extreme Weekly XTRM Score serves as a stark reminder of the technical damage inflicted on the chart. The transition from high-margin compounded drugs to lower-margin branded distribution will fundamentally alter the company's earnings power in the coming quarters. Because of this structural shift, the stock is approaching an interesting area, but it requires careful observation rather than blind accumulation. Investors asking why Hims is down should continue to monitor the $18.00 support level closely, waiting to see if the telehealth provider can prove its new business model is capable of sustaining long-term growth.